Hotgen(SH:688068) Shang Hai Zheng Quan Bao·2025-12-01 18:57Group 1 - The company, Beijing Hotgen Biotech Co., Ltd., plans to jointly invest in Beijing Yaojing Gene Technology Co., Ltd. with related parties, with a total investment of 80 million yuan [2][4] - The investment will be made at a price of 2 yuan per registered capital, increasing Yaojing Gene's registered capital from 110 million yuan to 150 million yuan, and reducing the company's equity stake from 40.91% to 38.00% [2][4] - The investment parties include Lin Changqing, the company's controlling shareholder and actual controller, and Beijing Yaojing Enterprise Management Center (Limited Partnership), which is associated with Lin Changqing [2][4] Group 2 - The related transaction has been reviewed and approved by the company's independent directors and the board of directors, with related directors abstaining from voting [3][12][13] - The transaction is classified as a related party transaction but does not constitute a major asset restructuring as defined by regulations [2][4] Group 3 - The investment aims to support the future development of Yaojing Gene and is expected to enhance the company's long-term investment returns without significantly impacting its financial status or operational performance [11][45] - The transaction is deemed fair and reasonable, with no harm to the interests of the company or its shareholders, particularly minority investors [11][45]